Breakthroughs for Obese Patients with VTE

What is the latest evidence for VTE prophylaxis and treatment in obese patients and how is this different from the current guidelines? In this activity, expert cardiology faculty cover the most recent data and guideline limitations on VTE prevention and management. Roundtable discussion is included to provide practical insight to help clinicians apply knowledge to their practice and help them optimize anticoagulant therapy and develop treatment plans in their obese patients.

Target Audience

This activity is intended for clinical cardiologists, vascular surgeons, interventional cardiologists, hematologists and primary care physicians.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Optimize anticoagulant therapy prophylactically and therapeutically in obese patients
  • Discuss limitations of various guideline recommendations for prophylactic and therapeutic anticoagulation in obese patients in the context of recent evidence
  • Interpret the latest data on DOACs for treating and protecting against thrombotic events in obese patients

Additional Information

Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit
Course opens: 
Course expires: 

Gregory Piazza, MD, MS
Associate Professor of Medicine
Harvard Medical School
Staff Cardiologist, Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

Christian T. Ruff, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Investigator, TIMI Study Group
Cardiovascular Division
Brigham and Women’s Hospital
Boston, MA

The following financial relationships have been provided:
Gregory Piazza, MD, MS
Consulting: Agile, Amgen, Boston Scientific Corporation, Pfizer
Grants: Bayer, Bristol Myers Squibb, Boston Scientific Corporation, Janssen, Portola

Christian Ruff, MD, MPH
Grants/Research Support (through institution): Anthos, AstraZeneca, Boehringer Ingelheim, Daiichi-Sankyo
Honoraria: Anthos, Bayer, Bristol Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Janssen, Pfizer, Portola
Grants/Research Support (through TIMI Study Group): Abbott, Amgen, Anthos Therapeutics, AstraZeneca, Daiichi-Sankyo, Eisai, Intarcia, MedImmune, Merck, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Roche, The Medicines Company, Zora Biosciences

Accredited Provider

This activity is provided by the Academy for Continued Healthcare Learning.

AMA PRA Category 1 CreditTM

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit
Please login or register to take this course.

This course is offered through myCME. 

To take this course you will be redirected to myCME's website. You must login or create an account with myCME in order to complete this activity. 

Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!